Business Wire

Asymchem Welcomes Franck Mevellec as Senior Director, Business Development

Share

Asymchem, a leading global CDMO, is excited to announce the appointment of Franck Mevellec as senior director, business development. Franck brings over 20 years of experience in the pharmaceutical industry, working across various aspects of drug development from R&D to sales.

Franck boasts a proven track record of success, having held key positions at industry leaders like Bayer Healthcare (R&D), Teva Pharmaceuticals (portfolio director), Minakem (BD director), and most recently, Seqens (global head of sales). He joins Asymchem with a focus on expanding the company’s footprint across Europe.

“Franck’s extensive experience and deep understanding of the European pharmaceutical market make him a valuable asset to our team,” said Jon Brice, SVP of business development at Asymchem. “His leadership and entrepreneurial spirit will be instrumental in driving our growth and strengthening our presence in this region.”

In his new role, Franck will leverage his expertise to develop new business opportunities for Asymchem, focusing on a wide range of services including flow chemistry, oligo and peptides, drug product development, and biologics.

About Asymchem

Asymchem is a leading global manufacturer of pharmaceutical ingredients and a trusted partner to pharmaceutical and biotechnology companies worldwide. With a robust track record and a deep commitment to quality and innovation, Asymchem offers a comprehensive range of services, including custom synthesis, process development, and manufacturing of small molecules, peptides, oligonucleotides, and biologics.

For inquiries: www.asymchem.com/contact.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jake Knorr
Senior Director of Marketing
Jakeknorr@asymchem.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DentalMonitoring Sets New Standard in Orthodontic Remote Monitoring With EU-MDR Certification14.6.2024 19:33:00 CEST | Press release

DentalMonitoring is proud to announce that the DentalMonitoring Software is now certified under the European Union Medical Device Regulation 2017/745 (EU MDR) and fulfills the requirements for CE marking as a class IIa medical device. European Medical Device Regulation 2017/745 (EU MDR) replaces the previous Medical Device Directive 93/42/EEC (MDD). EU MDR sets more rigorous requirements for clinical evaluation, risk management, post-market surveillance, and data collection on medical devices.(1) This landmark achievement underscores DentalMonitoring's commitment to advancing dental care through cutting-edge technology and rigorous regulatory compliance. Achieving this certification four years ahead of the deadline demonstrates DentalMonitoring's commitment to positioning itself as an innovative, serious, efficient, and safe player in the medical field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240614842101/en/ DentalMo

Argonne and a Moroccan University Sign Agreement to Advance Green Energy Tech and Computing14.6.2024 15:24:00 CEST | Press release

The U.S. Department of Energy’s (DOE) Argonne National Laboratory and University Mohammed VI Polytechnic (UM6P) have signed a memorandum of understanding (MOU) to collaborate on key areas of mutual interest related to green energy technology and the nexus of water and energy. In a ceremony held at UM6P’s campus in Benguerir, the MOU was signed by Argonne Laboratory Director Paul Kearns and UM6P President Hicham El Habti. “We are excited to see what discoveries and innovations will result from our ongoing partnership,” said Kearns. ​“By working together, we’ll open new scientific frontiers for both our countries’ futures.” “Today marks a significant milestone in our journey towards sustainable innovation. The signing of this Memorandum of Understanding with Argonne National Laboratory underscores our commitment to advancing research and development in renewable energy, energy grids, and water management. Together, we aim to leverage our collective expertise to create transformative solu

MultiBank Group Recognized as Top BaFin-Regulated Forex Broker14.6.2024 14:33:00 CEST | Press release

MultiBank Group is thrilled to announce its recognition as a top BaFin-regulated forex broker by FXEmpire, a leading financial markets authority. This prestigious accolade highlights MultiBank Group's unwavering commitment to excellence, security, and innovation in the forex trading industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240614306878/en/ Top BaFin regulated forex broker 2024 (Graphic: Business Wire) About BaFin: Regulating German Financial Markets BaFin, Germany's Federal Financial Supervisory Authority, oversees the country's banking, securities, and insurance sectors. It ensures fair and transparent operations in the forex and CFD markets by enforcing rigorous standards. Selection Methodology FXEmpire's methodology for selecting the best BaFin-regulated brokers includes: Regulation Verification: Ensuring each broker is BaFin-regulated, providing traders with high-level protection. Cost Efficiency: Brokers

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)14.6.2024 14:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license global rights to develop and commercialize olverembatinib in all territories outside of mainland China, Hong Kong, Macau, Taiwan and Russia. Despite the impact TKIs have had in the treatment of patients with CML, there remains significant unmet need for patients whose disease is resistant or refractory to these therapies or who develop hard-to-treat mutations following these treatments. “Takeda has a long history of driving important treatment advances for patients, particularly those with hematological cancers facing treatment gaps,” said Teresa Bitetti, president of the Globa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye